Adjuvant endocrine therapy for premenopausal women with early breast cancer

Ting Bao, Nancy E. Davidson

Research output: Contribution to journalComment/debatepeer-review

Abstract

Adjuvant endocrine therapy is a pivotal component of treatment for premenopausal women with early-stage hormone receptor-positive breast cancer. Currently, the standard endocrine therapy for premenopausal women is tamoxifen; a role for ovarian suppression or ablation has also been identified. Uncertainty remains about the optimal use of endocrine therapy in this setting. The role of ovarian suppression with tamoxifen or aromatase inhibitor, the optimal duration of adjuvant endocrine therapy and the utility of biomarkers and pharmacogenetic studies to select therapy are questions worthy of further investigation.

Original languageEnglish (US)
Article number115
JournalBreast Cancer Research
Volume9
Issue number6
DOIs
StatePublished - Dec 17 2007

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Adjuvant endocrine therapy for premenopausal women with early breast cancer'. Together they form a unique fingerprint.

Cite this